These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32214283)

  • 21. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
    Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
    Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
    Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
    J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
    Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
    J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
    Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
    BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis.
    Niedworok C; Panitz M; Szarvas T; Reis H; Reis AC; Szendröi A; Nyirády P; Szasz AM; Módos O; Rübben H; Vom Dorp F
    J Urol; 2016 Jun; 195(6):1690-6. PubMed ID: 26678957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer.
    Zhao J; Dong D; Sun L; Zhang G; Sun L
    Int Braz J Urol; 2014; 40(2):179-89. PubMed ID: 24856504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and Prognostic Implications of FGFR3
    Geelvink M; Babmorad A; Maurer A; Stöhr R; Grimm T; Bach C; Knuechel R; Rose M; Gaisa NT
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of immunohistochemical markers (PCNA, Ki-67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors.
    Vorreuther R; Hake R; Borchmann P; Lukowsky S; Thiele J; Engelmann U
    Urol Int; 1997; 59(2):88-94. PubMed ID: 9392055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
    Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
    Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunohistochemical study of p53 and Ki-67 overexpression in grade 3 superficial bladder tumor in relationship to tumor recurrence and prognosis].
    Ikegami S; Yoshimura I; Tsuji A; Seta K; Kimura F; Odajima K; Asano T; Hayakawa M
    Nihon Hinyokika Gakkai Zasshi; 2001 Nov; 92(7):656-65. PubMed ID: 11766364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
    Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
    Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. E-cadherin÷CD44 immunophenotype in the epithelial-mesenchymal transition of bladder urothelial carcinomas.
    Stepan AE; Pirici D; Bălăşoiu M; Novac MB; Drocaş AI; Ciurea RN; Stepan D; Gheonea DI; Simionescu CE
    Rom J Morphol Embryol; 2015; 56(1):85-91. PubMed ID: 25826491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of p53 and Ki-67 immunomarkers in carcinoma of urinary bladder.
    Thakur B; Kishore S; Dutta K; Kaushik S; Bhardwaj A
    Indian J Pathol Microbiol; 2017; 60(4):505-509. PubMed ID: 29323062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of N-E cadherin switch as an independent predictive parameter of bladder cancer survival outcomes].
    Cui D; Han BM; Jing YF; Xia SJ
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):380-3. PubMed ID: 22490896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.